Condition: Hyperparathyroidism · Kidney Transplantation Recipients · Sponsor: Aarhus University Hospital
This study aims to clarify whether surgical treatment of persistent hyperparathyroidism after kidney transplantation offers clinically meaningful benefits compared with a conservative treatment strategy. Kidney transplant recipients (\>6 mo after transplantation) with persistent hyperparathyroidism (elevated PTH and either hypercalcemia or hypophosphatemia) will be randomized in a 1:1 ratio to either subtotal parathyroidectomy or conservative management according to standard clinical practice. The study is conducted as an open-label, randomized controlled pilot trial with a 12-month follow-up period. Outcomes include bone density, physical function, quality of life and symptom burden.
This description comes directly from the study's public registry record.
Hanne S Jørgensen, MD, PhD · +45 51 41 35 41 · hsjorgensen@clin.au.dk
Amal Derai, MD · +45 51 36 03 80 · amader@rm.dk
Always discuss trial participation with your own doctor first.
| Departement of Nephrology, Aarhus University hospital | Aarhus, Central Jutland, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07415421